Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
October 22, 2025
Previous PostFDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Next PostUZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025
